[{"pageContent":"Pharmaceutical and Biotech \nCompanies: How Are They \nManaged?\nPUBPOL 2350\nOctober 26, 2023","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":1,"lines":{"from":1,"to":5}}}},{"pageContent":"2","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":2,"lines":{"from":1,"to":1}}}},{"pageContent":"3","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":3,"lines":{"from":1,"to":1}}}},{"pageContent":"4","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":4,"lines":{"from":1,"to":1}}}},{"pageContent":"5","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":5,"lines":{"from":1,"to":1}}}},{"pageContent":"Are you enjoying this course? \nThe Brooks School may be right for you! \nMajor in Health Care P\no\nlicy or Public Policy \nInternal Transfer Information Session \nWednesday, November 1, 2023 \n4:30PM \n–\n5:30PM in MVR 2250 \nQuestions?   \nBrooks_admissions@cornell.edu","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":6,"lines":{"from":1,"to":12}}}},{"pageContent":"8\nPrelim #2: Tuesday, October 31\nst\n \nat 7:30pm \n▪\nLast names beginning with... \no\n \nA \n–\n \nQ: \nKennedy/Call Auditorium (“our” classroom)\no\n \nR \n–\n \nS: \nMVR G151 \no\n \nT \n–\n \nZ :\n \nMVR G155\n▪\nCovers material from September 21\nst\n \nthrough \n    \ntoday’s \nlecture\n \n(the last slide we cover today)\n▪\nWe \ndo\n \nhave class on Tuesday, October 31\nst\n, \n    \nbut that material will be covered on the final","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":8,"lines":{"from":1,"to":48}}}},{"pageContent":"9\nAny Current Events?","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":9,"lines":{"from":1,"to":2}}}},{"pageContent":"Today’s First Set of Topics \n1)  How much more \ndo \nprivate \ninsurers pay health systems\n      \nrelative to Medicare\n2)  Implications of new health system reimbursement methods\n     \nfeatured in the Affordable Care Act (ACA)\n3)  Why doesn’t the government tax nonprofit hospitals?","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":10,"lines":{"from":1,"to":11}}}},{"pageContent":"1\nMedicare Cost \nEstimation\nGovernment estimates the \naverage cost of treating \nMedicare patients in each \nof the 750 different DRGs \nacross all 4,700 hospitals \nin the United States.  \n2\nPayment = Estimated \nCosts \nGovernment pays each \nhospital about 90% of \nthe estimated \nnational \naverage\n \ncost for each \nDRG (so hospitals lose \nmoney, on average).  \n3\nHospitals With High \nCosts Will Lose $\nThis payment is the same \nregardless of how long the \npatient spends in the hospital \nor how many services the \npatient receives (e.g., whether \nthey hire a lot of nurses or use \nexpensive surgical equipment).\nMedicare Instituted the Diagnosis\n-\nRelated Group (DRG) \nPayment System in 1983\nAn \nefficient\n \nhospital\ncan make $","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":11,"lines":{"from":1,"to":40}}}},{"pageContent":"12\nSource: Whaley et al., RAND, 2022.\n224%\nAverage\nAs With Physicians, Private Health Insurers Pay\nHospitals \nMuch\n \nMore Than Medicare (and Medicaid):\nfrom 75% to 250% More Across States","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":12,"lines":{"from":1,"to":10}}}},{"pageContent":"Insurers Are Trying to Shift Hospitals and MDs From Volume\n-\nBased (e.g., DRGs) to Value\n-\nBased Reimbursement \nMethods\n.\n3\n \nPrograms\n \nIntroduced\n \nby\n \nthe\n \nACA\n.\n1\nPay \n–\n \nfor \n–\n \nPerformance (P4P)\n2\nBundled Payments\n3\nAccountable Care \nOrganizations (ACOs)\nHigher pay for \nhigher quality, and \nlower pay for lower \nquality (we’ll discuss \nnext week).\nAsk MDs and hospital \nto divide a \nsingle\n \npayment.  Fosters \ncoordination.  See next \nslide\nAn insurer shares \ncost savings with a \nhealth system and \nits MDs.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":13,"lines":{"from":1,"to":48}}}},{"pageContent":"14\nWith a \nSingle, Bundled Payment\n, the MD and Hospital \nShould Work Together to Reduce Costs\n1.\nMD schedules elective \nsurgery; refers pt. to hosp. \nfor pre\n-\nadmission tests\n \n2.\nPatient admitted; \ntransported to operating \nroom\n \n3.\nMD performs surgery w/ \nRN, OR tech, surgical \nsupplies, anesthesiologist\n4.\nPatient recovers in \nRecovery Room\n5.\nMD admits patient to \nCoronary Care Unit: 1 RN \nfor every 2 patients\n6.\nMD visits pt.; orders lab tests, \nx\n-\nrays, medication. Hospital \nstaff perform tests and \nadministers medication\n8.\nMD transfers patient to \nMed/Surg unit for days \n3\n-\n4.  1 RN for every 6 \npatients.\n \n \n7.\nPatient complains of \ncomplications. Resident on\n-\nduty calls MD and \nadministers treatment.\n10.\nMD and hospital SPLIT a \nsingle payment\n.\n9.\nMD discharges patient \nto:\n \nhome, \nskilled nursing facility (SNF), rehab \nhospital. May recommend home \ncare.\nPhysician\nRN = registered nurse; OR = operating room","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":14,"lines":{"from":1,"to":64}}}},{"pageContent":"The ACA Created the Accountable \nCare Organization (ACO) Program","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":15,"lines":{"from":1,"to":2}}}},{"pageContent":"The ACA Created the Accountable Care Organization (ACO) \nProgram: an Example\n01\n02\n03\n04\n05\n06\n07\nA group of MDs and hospitals agree to be accountable \nfor the quality and \ncost of care provided to a group of Medicare patients (e.g., 20,000 Medicare \npatients in Boston treated by Mass General health system and its MDs).\nStart Date: \nVoluntary program that began in 2012.\nMedicare \nforecasts those patients’ costs\n \nfor next year based on patients’ \nprevious 3 years of Medicare spending (e.g., $10,000 per Medicare beneficiary).\nHospitals and physicians continue to be paid fee\n-\nfor\n-\nservice \n(MDs by the RBRVS \nsystem; hospitals by DRG system).\nIf quality and cost targets are met, the \nACO receives about 50% of the \nsavings\n \nand \nMedicare keeps the \nrest.\nExample: \nif Medicare only spent $9,600 per person, Mass General would receive \na $4 million bonus payment ($400 X 50% X 20,000).  Mass General \nwould\n \nowe \ngovernment \nmoney\n \nif actual spending exceeds the target.\nCost forecast/benchmark recalculated each year.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":16,"lines":{"from":1,"to":45}}}},{"pageContent":"ACO Results: Not Exactly Bending the Cost Curve\nIn 2021, 58% of ACOs earned shared saving payments, up \nfrom 31% in 2016.\nProviders received shared savings of $2.0 billion in 2021, while \nsaving Medicare $1.9 billion.  Smaller savings than expected.\nAverage \nshared savings of \nonly\n \n$\n2 million \nper year \nfor \nthose \nACO\n \nreceiving \nshared \nsavings\n.\nACOs led by a physician group have been much more \nsuccessful than those led by a health system.\n01\n02\n03\n04\nSource: CMS, 2022; National Association of ACOs, August 20, 2018;\nMcWilliams et al., NEJM, September 20, 2018.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":17,"lines":{"from":1,"to":28}}}},{"pageContent":"Health Systems That Can Gain the Cooperation \nof Physicians and Work Effectively With Physicians\nare More Likely to Reduce Costs, Improve \nQuality, and Thrive Under Value\n-\nBased \nReimbursement Systems\nThis helps explain why hospitals have\nbeen buying physician practices and\nemploying physicians recently\n(besides trying to capture more of \nthe physicians’ \nadmissions\n \nand the \np\nrofits from\n \nthe\n \nfacility\n \npayment\ns\n)","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":18,"lines":{"from":1,"to":25}}}},{"pageContent":"How the ACA is messing\nup the health care system\nhttp://www.cc.com/video\n-\nclips/cbbn22/the\n-\ndaily\n-\nshow\n-\nwith\n-\njon\n-\nstewart\n-\nthird\n-\nworld\n-\nhealth\n-\ncare\n---\nknoxville\n--\ntennessee\n-\nedition\nAnd now, for something completely different...","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":19,"lines":{"from":1,"to":30}}}},{"pageContent":"Role of Nonprofit Hospitals\n▪\n \n20% of U.S. hospitals are for\n-\nprofit: they pay sales, \n   \nproperty, and corporate income taxes that help pay for \n   \ngovernment programs (e.g., education, Medicaid).\n▪\n \n80% of hospitals are nonprofit: they don’t pay \nany\n   \ntaxes.  In 2020, these hospitals saved $28 billion by \n   \nnot being taxed.\nWhy would the government allow so many \nhospitals to avoid paying taxes?\nSource: Bai et al., \nJAMA Network Open\n, 2022; \nKaiser Family Foundation, 2023.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":20,"lines":{"from":1,"to":24}}}},{"pageContent":"Nonprofit Hospitals Provide Substantial Benefits to\nTheir Communities in Lieu of Paying Taxes\n•\nIn 2020, nonprofit hospitals spent only $16 billion on free/\n      \ncharity care to patients who are uninsured and can’t pay.\n•\n% of a hospital’s costs devoted to charity care:\n•\nNonprofit hospitals\n \n2.3% \n(less than for\n-\nprofit hospitals!)\n•\nFor\n-\nprofit hospitals\n \n3.8%\n•\nGovernment hospitals:\n \n4.1%\n•\nBetween 2012 and 2019, nonprofit hospital profits grew by 36%\n     \nbut charity care didn’t \nincrea\ns\ne \nat all.\n•\nSome states \nar\ne\n \nthreaten\ning\n \nto begin taxing nonprofit hospitals. \n•\nBecause the uninsured rate is now lower due to the ACA, some \n     \npolicy makers think nonprofit hospitals should increase the \n     \nbenefits they provide to their communities.\nSource: Bai et al., \nJAMA Network Open\n, 2022; Bai et al., Health Affairs, 2021; \nJenkins and Ho, 2023; Rosenbaum et al., \nHealth Affairs\n, July 2015.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":21,"lines":{"from":1,"to":54}}}},{"pageContent":"Conclusions on Hospitals/Health Systems\n▪\n \nHospitals must attract physicians (and their patients) in \n   \norder to generate revenue/profit.\n▪\n \nHospitals used to compete with one another for physicians’\n   \nloyalty by offering expensive medical technologies.\n▪\n \nHospitals \nstill do this\n, but also try to attract patients from\n   \nhealth insurers by cutting costs, and accepting lower prices\n   \nin order to\n \nbe included in an insurer’s network. \n▪\n \nMedicare’s DRG system creates incentives for hospitals to\n   \nreduce costs and get patients out of the hospital faster.\n▪\n \nThe ACA \nusher\ned\n \nin new reimbursement methods (i.e.,\n   \nnot volume\n-\nbased) that encourage physicians and hospitals \n   \nto \nwork together\n \nto reduce costs and improve quality. \n▪\n \nNonprofit hospitals receive substantial tax savings in \n   \nexchange for providing charity care and other benefits.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":22,"lines":{"from":1,"to":48}}}},{"pageContent":"Today’s Next Focus: View the World from a \nPharmaceutical or Biotech Company’s Perspective \n1.\nDevelopment and Approval: \nDiscuss how new drugs are \ndeveloped. How long does it take and how much money is \nrequired, on average?\n2.\nGovernment’s Role: \nDescribe the government’s critical role in \ndrug development\nTuesday: discuss key policy issues in the \nbiopharmaceutical industry","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":23,"lines":{"from":1,"to":13}}}},{"pageContent":"Developing a New Drug is a Long, Uncertain, and Expensive\nProposition: \nTypical \nTimeline\nYears\nDrug Development Timeline\nF\nood and Drug \nAdmin. (FDA)\n \nReview\nPhase 2\n100\n–\n300 Patient Volunteers Used to \nLook for Efficacy \n–\n \nDoes the Drug \nWork?\nPreclinical Testing\nLaboratory and Animal Testing\n16\n14\n12\n10\n8\n6\n4\n2\n0\nDiscovery\n(2\n–\n10 Years)\nPhase 1 \n20\n–\n80 Healthy Volunteers Used to \nDetermine Safety and Dosage\nPhase 3\n1,000\n–\n5,000 Patient Volunteers\nEffective in \nl\narge \ns\nample\n?\nSide\n \neffec\nt\ns \nwith\n \nl\nong\n-\nt\nerm \nu\nse\n?\nAdditional Post\n-\nMarketing \nTesting\nSource: PhRMA Pharmaceutical Industry Profile 2003, Chapter 1: Increased Length and Complexity of the \nResearch and Development Process. DiMasi, JA, Hansen, RW, Grabowski, HG. “The Price of Innovation: new \nestimates of drug development costs.” \nJournal of Health Economics\n. 2016.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":24,"lines":{"from":1,"to":74}}}},{"pageContent":"Source: Campbell, 2008. \n▪\n \nUnderstand how a disease works. \n▪\n \nHypothesize how a drug/compound might intervene in \n   \nthe disease process.\n▪\n \nIdentify compounds that have favorable properties: \n   \nlikely to be effective, but not likely to be (too) toxic.\n▪\n \nTest those compounds with \nin vitro \n(cells in the lab)\n   \nand \nin vivo\n \n(animals with the disease) methods.\n▪\n \nPick a winning compound: discovery and preclinical \n   \nresearch is much less expensive than clinical (i.e., \n   \ntesting on humans) research. \n▪\nFile \nactive ingredient and method of use patents\n \nto \nprotect intellectual property.\nEarly Stages of Drug Development: Searching for\nBrilliant Insights in the Discovery and Preclinical Phases","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":25,"lines":{"from":1,"to":39}}}},{"pageContent":"Developing a New Drug is a Long, Uncertain, and Expensive\nProposition: Success by Stage\n5,000\n–\n10,000\n \nScreened\n \nin \nDiscovery\n250\nEnter Preclinical \nTesting\n8\nEnter \nClinical \nTesting\nNew Drug Success \nRates by Stage\n1\nApproved \nby the FDA\nSource: PhRMA Pharmaceutical Industry Profile 2003, Chapter 1: Increased Length and Complexity of the \nResearch and Development Process. DiMasi, JA, Hansen, RW, Grabowski, HG. “The Price of Innovation: new \nestimates of drug development costs.” \nJournal of Health Economics\n. 2016.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":26,"lines":{"from":1,"to":27}}}},{"pageContent":"The Government’s Role\n•\nApprove patents, where appropriate (we’ll discuss this later).  \nUsually filed in the discovery \nan\nd\n \npreclinical phase.\n•\nSafety and efficacy\n•\nDetermine whether compounds are safe enough to be tested on \nhumans (right before Phase 1).\n•\nWork with pharmaceutical firms to determine appropriate \nhealth outcomes to measure during Phases 2 \n–\n \n3.\n•\nAfter Phase 3, evaluate the drug’s performance: is there a \nstatistically significant improvement in health outcomes (e.g., \nsurvival, blood sugar levels) among patients in the experimental \ngroup vs. patients in the control group?\n•\nPost\n-\napproval surveillance: monitor \nsafety/adverse \nincidents \namong patients \nwhen \nthe drug is more widely used.\n•\nMonitor and approve drug manufacturing facilities.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":27,"lines":{"from":1,"to":35}}}},{"pageContent":"12% of Drugs That Start Phase 1 are Approved, and it Takes\nan Average of 8 Years (same % with more recent data) \nNote: Mean time between phases is \nreported\nIn (parentheses)\n60%\n36%\n62%\n90%\n12%\n0%\n10%\n20%\n30%\n40%\n50%\n60%\n70%\n80%\n90%\n100%\nPhase 1\n-\n2\n(1.7 years)\nPhase 2\n-\n3\n(2.5 years)\nPhase 3\n-\nNDA/BLA\nSub\n(2.6 years)\nNDA/BLA Sub\nNDA/BLA App\n(1.3 years)\nPhase 1\n-\nNDA/BLA\nApp\n(8.1 years)\nTransition Probability (%)\nPhase Transition Probabilities and Overall Clinical Approval \nSuccess Rates\nSource:  DiMasi  et al. 2016.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":28,"lines":{"from":1,"to":46}}}},{"pageContent":"Drug Development Case Study: Eli Lilly Was Ready to Test \nMounjaro\n \nin a Phase 3 Type\n-\n2 Diabetes Trial in Late 2019\n▪\nMost Type\n-\n2 diabetes patients take a generic drug, metformin, by \nitself or in combination with another drug from a different class \nwith a different mechanism of action (+ exercise and healthy diet).\n▪\nHowever, many patients \nstill \ndo \nnot meet the recommended \nblood sugar level \n(\ni.e., \nan \nHbA1c \nlevel \nof \nless than 7.0).\n▪\nMounjaro\n \n(brand name) is a GLP\n-\n1 receptor agonist.\n▪\n“\nTirzepatide\n \n(scientific/generic name) lowers fasting and \npostprandial glucose concentration, decreases food intake, and \nreduces body weight in patients with type\n2 diabetes” (from \nMounjaro’s\n \nlabel).","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":29,"lines":{"from":1,"to":42}}}},{"pageContent":"Mounjaro’s\n \nPhase 3 Randomized Controlled Trial (RCT)\nIn 4 \nseparate trials\n, \nMonjaro\n \nwas compared \nw/o\n \nmetformi\nn\n \nvs. a \nplacebo; and separately versus 3 insulin drugs.\nPatients with \n(uncontrolled) \nType\n-\n2\nDiabetes\nN = 469\nN = 468\nMounjaro\n \n+ metformin\nOzempic + metformin\nEfficacy:\n   \n-\n \nReduction in HbA1c\n \n2.3\n \n \n \n1.8\n   \n-\n \n% patients hitting 7.0\n \n86% \n                            \n79%\n   \n-\n \nPounds lost\n \n \n28\n \n \n  \n13\n% of patients with: \n   \n-\n \nAbdominal pain\n \n5%\n \n \n  \n4%\n   \n-\n \nDiarrhea\n \n \n18%\n \n \n  \n9%\n   \n-\n \nNausea\n \n \n17%\n \n \n  \n4%\n   \n-\n \nVomiting\n \n \n9%\n \n \n  \n2%\nControl\nGroup\nTreatment\nGroup\nPrimary\nEndpoint\nSecondary\nendpoint","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":30,"lines":{"from":1,"to":110}}}},{"pageContent":"1)\nShould the Food and Drug \n      \nAdministration (FDA) approve \n           \nMounjaro\n?\n    \n2)  What decision rule does the FDA use?","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":31,"lines":{"from":1,"to":9}}}},{"pageContent":"How the FDA Makes Approval Decisions\nFDA’s decision rule: \nAre \nthe \nhealth \nbenefits\n \n(actual or \nexpected) \nbetter \nthan \nor same as the \ncontrol group?  \nIf so, do the health \nbenefits \noutweigh the \npossible side effects\n \nor safety issues? \nPhase 4 Studies\nThe FDA often mandates \nPhase 4 (\npost\n-\napproval\n) \nstudies as a condition for \napproval, to explore \nwhether safety issues in \na RCT persist in a \nbroader patient \npopulation.\nNOT Prices \nThe FDA \ndoes not\n \nconsider the drug’s \nprice.  Ditto with\nEuropean regulatory\nbodies.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":32,"lines":{"from":1,"to":40}}}},{"pageContent":"Mounjaro’s\n \nApproved Label\nPhysicians can use a drug “off\n-\nlabel” once it is approved. \n•\nMounjaro\n \nfor Type\n-\n1 diabetes, for example\n•\nMounjaro\n \nfor weight loss for non\n-\nType\n-\n2 diabetes \npatients\n, for example\nBut pharmaceutical firms \ncannot market off\n-\nlabel\n, and \nhealth insurers are more likely to refuse to pay when a \ndrug is used off\n-\nlabel (and/or to require prior \nauthorization).\nFDA Approves a Drug \nfor an Indication\n, Not a Drug","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":33,"lines":{"from":1,"to":35}}}},{"pageContent":"About 20% of Prescriptions Are for Off\n-\nLabel \nUses, and a Majority for Some Drugs\nPhysician Determination of \nOn\n-\n \nvs Off\n-\nLabel \nIn a separate survey of 1,200 \nphysicians, only \n55% could \ncorrectly determine \nwhether or \nnot\n \na particular \nuse of a drug was \non\n-\nlabel (supported by RCT \nevidence) or off\n-\nlabel.\nOff\n-\nLabel Prescription Efficacy \nOnly 30% of off\n-\nlabel \nprescriptions were \nsupported by \nevidence of clinical efficacy \n(e.g., \nresults from a published study \nafter\n \nthe drug was approved).\nSource: Pan, \nClinical Pharmacology & Therapeutics\n, May 2012.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":34,"lines":{"from":1,"to":43}}}},{"pageContent":"Why Are Biotech and Pharmaceutical Firms Willing \nto Spend So Much to Develop a New Drug?\n179\n413\n1044\n2558\n1970s\n1980s\n1990 - early\n2000s\n2013\nSource: \nDiMasi\n \net al., 2016,  \nJournal of Health Economics\n.\nTotal Cost:\nRepresents the \ntotal amount \nneeded to spend \non a drug \nportfolio to be \n“assured” \nstatistically \nthat \none will be \napproved\nDrug Development Cost\n($ Millions, in real terms)","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":35,"lines":{"from":1,"to":30}}}},{"pageContent":"36\nPatents\n \nAllow a Firm to Recover R&D Costs; \nExpiration Triggers Fierce Competition\nGeneric Protection\nPatents\n \nprevent other \nfirms from producing a \ngeneric\n, or bioequivalent, \ncopy of a drug for the 20\n-\nyear life of a patent.\nBioequivalent Competitors\nWithout patent protection, any firm \ncould take a drug the day it is approved \nby the FDA and \n“reverse\n-\nengineer\n” \nit. \nThey could sell a bioequivalent version \nof the drug \nwithout having invested \nmillions of dollars developing it. \nCompetitive Pricing \nMultiple firms in \ncompetition would \nlead to \ndrug prices close to \nproduction cost\n, meaning \nresearch\n \nand\n \ndevelopment\n \n(R&D)\n \ncost\ns\n \ncouldn’t be \nrecouped.\nPatent Pricing\nPatents allow a firm to \ncharge a price above the \ncost of producing\n \nthe \ndrug to make a profit and \nrecoup R&D costs.\nhttps://\nwww.iconfinder.com\n/\nmrpixel\nhttps://\nwww.iconfinder.com\n/\niconsets\n/security\n-\ndouble\n-\ncolour\n-\nblue\n-\nblack\n-\nvol\n-\n3\nhttps://\nwww.iconfinder.com\n/\nlaurareen","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":36,"lines":{"from":1,"to":81}}}},{"pageContent":"37\nProduct Life Cycle: Revenue Grows Steadily \nOver an Extended Time, Then Falls Precipitously\nSource: DiMasi and Grabowski, 2012.\n-100\n-50\n0\n50\n100\n150\n200\nMillions of 2000 Dollars\nYear\nDrug\nLaunch\nPatents \nallow a firm \nto set a price \nabove \nproduction \ncosts\nRed line = profit of the drug\nLosses when\ndeveloping drug\nGeneric entry \ndecreases \nprofits\nonce\npatents\nexpire","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":37,"lines":{"from":1,"to":30}}}},{"pageContent":"38\nSource: \nDusetzina\n \net al., 2023\nLoss Drivers\n•\nAutomatic \nsubstitution at \npharmacy \n•\nHealth \ninsurers set \nlower co\n-\npays \nfor generic \nversus \nbranded drugs\nOnce Patents Expire Generic Versions Enter and 97% of Patients \nEventually Shift From the Branded to a Generic Product","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":38,"lines":{"from":1,"to":21}}}},{"pageContent":"Generics Cut the Price Substantially Once They Enter","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":39,"lines":{"from":1,"to":1}}}},{"pageContent":"Generic Drugs Now Account for 91% of Prescriptions Filled\n(but a Much Smaller % of Pharma Spending)\nGeneric Share of Total Prescriptions, 1984\n-\n2022\n18.6\n32.0\n36.0\n49.7\n56.4\n74.5\n80.0\n86.0\n88.0\n88.7\n89.5\n90.0\n90.0\n90.0\n90.0\n91.0\n1984\n1989\n1994\n1999\n2004\n2009\n2011\n2013\n2014\n2015\n2016\n2017\n2018\n2019\n2020\n2022\nYears\nSources: For\n1984\n-\n2004, IMS Health\nNational Prescription Audit archives; for 2005\n-\n2009, IMS Health \nNational Sales Perspectives; 2010\n-\n2012, IMS; GPHA, 2015; for 2018, IQVIA Medicine Use and Spending in \nthe U.S., May 2019.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Management_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231026105727-04'00'","ModDate":"D:20231026105727-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-26T10:57:27-04:00","xmp:modifydate":"2023-10-26T10:57:27-04:00","xmpmm:documentid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC","xmpmm:instanceid":"uuid:1AC17B96-2DDC-41C1-A3EB-93F299F629DC"}},"totalPages":40},"loc":{"pageNumber":40,"lines":{"from":1,"to":49}}}}]